NASDAQ:RYTM - Rhythm Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$31.50 -1.27 (-3.88 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$32.77
Today's Range$31.25 - $33.20
52-Week Range$16.80 - $37.23
Volume162,900 shs
Average Volume174,276 shs
Market Capitalization$880.41 million
P/E Ratio-11.13
Dividend YieldN/A
Rhythm Pharmaceuticals logoRhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. is a subsidiary of Motus Therapeutics, Inc.

Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio24.85
Quick Ratio24.85


Trailing P/E Ratio-11.13
Forward P/E Ratio-18.98
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.31 per share
Price / Book5.93


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares27,530,000
Market Cap$880.41

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) issued its earnings results on Monday, May, 14th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.15. View Rhythm Pharmaceuticals' Earnings History.

What price target have analysts set for RYTM?

4 analysts have issued 12-month price targets for Rhythm Pharmaceuticals' stock. Their predictions range from $23.00 to $42.00. On average, they anticipate Rhythm Pharmaceuticals' share price to reach $33.75 in the next year. This suggests a possible upside of 7.1% from the stock's current price. View Analyst Ratings for Rhythm Pharmaceuticals.

What is the consensus analysts' recommendation for Rhythm Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (6/16/2018)
  • 2. Needham & Company LLC analysts commented, "We hosted a series of mtgs with mgmt and investors last wk. Enrollment in setmelanotide Phase 3 trial in POMC patients is nearing completion. Mgmt did not disclose current enrollment figure, but did reiterate guidance for completion in 1H18. Phase 3 trial in LepR patients has been initiated. Mgmt still expects to complete enrollment of this latter trial by YE18, noting help from an overlap in sites w/ POMC trial and higher prevalence. A mtg w/ FDA to discuss Bardet-Biedl Phase 3 design is scheduled. Trial likely to be somewhat larger, but it is not yet clear whether a placebo arm will be needed. We expect initial data from Phase 2 testing in Alstrom, Epigenetic POMC, and possibly Heterozygous POMC patients in 1H18. Mgmt did not guide on timing for an update on Bardet-Biedl Phase 2 trial, but did convey a bias towards expectations for a more profound impact on weight loss w/ longer duration treatment. Reiterate BUY. We believe Phase 2 POMC and LepR data are compelling and have high conviction around positive Phase 3 outcomes in 2019. We believe stock has room for upside around positive Phase 2 trial updates in 1H19, which would expand peak sales potential." (2/26/2018)
  • 3. Cowen Inc analysts commented, "Rhythm released Q3 financials this morning, following the presentation of promising." (11/14/2017)

Are investors shorting Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals saw a increase in short interest in June. As of June 29th, there was short interest totalling 1,182,591 shares, an increase of 127.4% from the June 15th total of 520,100 shares. Based on an average daily volume of 823,935 shares, the days-to-cover ratio is currently 1.4 days. Approximately 6.4% of the shares of the company are short sold. View Rhythm Pharmaceuticals' Current Options Chain.

Who are some of Rhythm Pharmaceuticals' key competitors?

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the folowing people:
  • Dr. Keith Michael Gottesdiener, Exec. Director (Age 64)
  • Dr. Fred T. Fiedorek M.D., Chief Medical Officer (Age 63)
  • Mr. Hunter C. Smith, CFO & Treasurer (Age 49)
  • Mr. Leonardus H.T. van der Ploeg Ph.D., Chief Scientific Officer (Age 63)
  • Ms. Nithya Desikan, Chief Commercial Officer (Age 39)

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Has Rhythm Pharmaceuticals been receiving favorable news coverage?

Media headlines about RYTM stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a coverage optimism score of 0.09 on Accern's scale. They also assigned headlines about the company an impact score of 45.32 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $31.50.

How big of a company is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals has a market capitalization of $880.41 million. The company earns $-33,700,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis. Rhythm Pharmaceuticals employs 26 workers across the globe.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]

MarketBeat Community Rating for Rhythm Pharmaceuticals (NASDAQ RYTM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.